Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in District of Columbia: - Kaiser Permanente-Capitol Hill Medical Center — Washington D.C., District of Columbia
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in District of Columbia: - MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in District of Columbia: - Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in District of Columbia: - Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- Washington Cancer Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in District of Columbia: - Washington Cancer Institute at MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in District of Columbia: - MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in District of Columbia: - Georgetown University — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this …
Sponsor: Jose Pablo Leone
NCT ID: NCT05501704
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in…
Sponsor: Yale University
NCT ID: NCT06923527
Sites in District of Columbia: - Lombardi Comprehensive Cancer Center at Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone mar…
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT04841148
Sites in District of Columbia: - Georgetown University — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How…
Sponsor: George Washington University
NCT ID: NCT06806930
Sites in District of Columbia: - George Washington-Medical Faculty Associates — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…
Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in District of Columbia: - Sibley Hospital - Johns Hopkins University — Washington D.C., District of Columbia
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in District of Columbia: - Research Site — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The investigators propose a randomized controlled clinical trial in 250 women with a history of early stage breast cancer who are overweight or obese with insomnia to test whether a brief, cognitive-behavioral intervention for insomnia (CB…
Sponsor: Johns Hopkins University
NCT ID: NCT05780814
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
Traditional clinical trials in patients with breast cancer leptomeningeal disease (LMD) are challenging as patients often have a rapidly progressive course and prognosis is poor, making meeting standard eligibility difficult. Furthermore, …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06638294
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening …
Sponsor: Georgetown University
NCT ID: NCT05130606
Sites in District of Columbia: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care …
Sponsor: Georgetown University
NCT ID: NCT06892275
Sites in District of Columbia: - Georgetown University — Washington D.C., District of Columbia